GI CANCERS

FDA approves Guardant360 CDx for identifying BRAF V600E-mutant colorectal cancer patients, enhancing precision therapy with encorafenib and cetuximab.

Experts discuss optimizing NALIRIFOX treatment for metastatic pancreatic cancer, highlighting flexible dosing and early adverse event recognition for better patient outcomes.

Zenocutuzumab shows promising efficacy in advanced NRG1+ pancreatic and cholangiocarcinoma, offering hope for patients after disease progression.

New trial data reveals promising results for pelareorep and atezolizumab in treating advanced anal cancer, significantly improving response rates and duration.

New research highlights amivantamab's potential in enhancing treatment outcomes for RAS/BRAF wild-type metastatic colorectal cancer, addressing resistance to standard therapies.

Investigational therapy [212Pb]VMT-α-NET shows promising antitumor activity in advanced neuroendocrine tumors, with ongoing trials and favorable safety profile.

New data reveals that elraglusib combined with chemotherapy significantly improves survival rates in metastatic pancreatic cancer patients, offering hope for better outcomes.

A novel oral fascin inhibitor, NP-G2-044, shows promise in treating pancreatic cancer, earning FDA orphan drug designation for innovative therapies.

New trial data highlight zanidatamab's potential to enhance survival in HER2-positive gastroesophageal adenocarcinoma, challenging existing treatment standards.

A recent study reveals that combining mFOLFOX6 and bevacizumab with atezolizumab significantly enhances progression-free survival (PFS) in patients with metastatic colorectal cancer.

New research highlights the benefits of physical activity, particularly walking, in reducing cancer-related fatigue and enhancing quality of life for colorectal cancer survivors.

A new integrated treatment regimen significantly enhances PFS vs standard chemotherapy in metastatic pancreatic cancer.

The FDA designates ARB1002 as an orphan drug, highlighting its potential as a novel treatment for pancreatic cancer amid limited options.

A groundbreaking blood test for colorectal cancer shows enhanced sensitivity, promising earlier detection and improved patient outcomes in upcoming studies.

Jason S. Starr, DO, discusses his approach to dose reduction of cabozantinib in patients with neuroendocrine tumors.

CPI-008 receives orphan drug designation, enhancing surgical imaging for pancreatic cancer and promising improved outcomes in challenging surgeries.

Breakthroughs in GI cancer treatment in 2025 showcase innovative therapies, including daraxonrasib for pancreatic cancer and aspirin's role in colorectal cancer recurrence.

A new study reveals FOLFIRINOX chemotherapy is feasible for select elderly patients with pancreatic cancer, highlighting safety and survival outcomes.

FDA approves CBI-1214 for colorectal cancer, enabling fast-tracked clinical trials and highlighting innovative T-cell engager technology.

The FDA fast-tracks BGB-B2033, a promising bispecific antibody, for advanced hepatocellular carcinoma, enhancing treatment options for patients.

Maen Abdelrahim, MD, PhD, discusses how to manage the dose of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma.

Pelareorep shows promising results in treating KRAS-mutant metastatic colorectal cancer, achieving a 33% response rate and improved survival outcomes.

FDA fast-tracks muzastotug and pembrolizumab for metastatic colorectal cancer, showcasing promising efficacy and safety in early studies.

Givastomig shows promising antitumor activity and a manageable safety profile in patients with CLDN18.2-positive gastroesophageal carcinoma.

FDA approves durvalumab with FLOT chemotherapy for early-stage gastric cancer, showing promising survival rates in recent clinical trials.